Alternatively, since CCL2 is central to the inflammatory process and it could up-regulate the release of CCL5 from endogenous pre-made vesicles in breast cancer cells, it is reasonable that the mouse tumors expressing both DARC and D6 significantly reduced mouse CCL2, thus resulting in significantly lower mouse CCL5 level detected in those tumors. The gene discussed is CCL2; the disease is breast cancer.